New way to deliver chemo directly to brain tumors tested in small study

NCT ID NCT05773326

Terminated Disease control Sponsor: Nader Sanai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a single dose of the cancer drug temsirolimus, given directly into the brain's blood supply, for people with recurrent high-grade glioma (a fast-growing brain tumor). Only 5 participants were enrolled, and the study was terminated early. The main goal was to measure how much drug reaches the tumor tissue, not to determine if it works as a treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: temsirolimus (a cancer drug given directly into the brain's blood supply)
What this could lead to: If it works, this could point toward a more targeted way to deliver chemotherapy for aggressive brain tumors.
What could go wrong: This is a very early, tiny trial (only 5 people) that was terminated early. It only tests drug levels, not whether the drug actually helps patients live longer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOMA GLIOMA, MALIGNANT HIGH GRADE GLIOMA

Contacts and locations

Locations

St. Joseph's Hospital and Medical Center

Phoenix, Arizona, 85013, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.